We’ve all seen it: PTSD that won’t budge. Patients try sertraline or paroxetine—the so-called “gold standards”—and walk away with little more than side effects and a sense of failure.
Enter a new contender: brexpiprazole + sertraline.
A recent Phase 3 randomized controlled trial might finally offer something real for those stuck in the PTSD trenches.
🚨 The Results
In a study across 86 sites with over 550 adults, adding brexpiprazole (2–3 mg) to sertraline (150 mg) led to a 5.6-point greater reduction on the CAPS‑5 (the gold-standard PTSD measure) compared to sertraline + placebo. That’s not a marginal win—it’s a clinically significant shift, especially in a treatment-resistant population.
Responder rates tell the story even clearer:
68.5% of patients on the combo had ≥30% reduction in symptoms
Compared to 48.2% on sertraline alone
That’s a +20% absolute response rate boost
And the improvements weren’t just short-lived. Benefits held through 12 weeks, even during a post-treatment observation period. No relapse, no rebound—just stability.
🧩 More Than Symptom Checklists
It wasn’t just about PTSD symptoms. This combo also:
Improved psychosocial functioning (B-IPF scores)
Reduced anxiety and depression (HADS)
Lowered global illness severity (CGI-S)
Helped with all symptom clusters, including reexperiencing, avoidance, and hyperarousal
That’s rare. Most meds in psychiatry hit one or two domains and leave the rest hanging. This one made a dent where it counts: function, resilience, and real-world relief.
⚠️ What About Side Effects?
Brexpiprazole is still an atypical antipsychotic, so there’s baggage. But the trial data suggest it’s relatively well-tolerated:
Fatigue: 6.8%
Weight gain: 5.9%
Somnolence: 5.4%
Discontinuation due to AEs? Just 3.9%, vs 10.2% in placebo.
No new safety signals. No psychosis worsening. Not perfect, but not the metabolic disaster zone we see with other agents.
🚀 What’s Next?
The FDA is reviewing this combo
For those of us treating chronic PTSD, this may be a real tool—not just a shiny new molecule with good marketing.
Until then, it’s worth paying attention. Because when sertraline alone doesn’t cut it—and we know it often doesn’t—this combo could offer a lifeline.
Psychiatrists could do the profession—and their patients—a great service by resisting the urge to medicalize every behavioral problem, impulsive act, or mood fluctuation as a direct manifestation of psychiatric illness. While genuine psychiatric disorders exist and require careful diagnosis and treatment, many of the struggles patients face are deeply rooted in the complexities of life itself—financial stress, relationship conflicts, loss, trauma, and systemic issues that no DSM diagnosis can fully capture.
When Life Struggles Are Mistaken for Mental Illness
Certain behaviors and emotional responses are frequently overpathologized. For example:
A teenager acting out in school following their parents’ divorce may be labeled with oppositional defiant disorder, when their reaction is a predictable response to emotional distress.
A grieving spouse who experiences sadness, tearfulness, and withdrawal beyond a few weeks might be diagnosed with major depressive disorder, despite bereavement being a normal and deeply personal process.
A person engaging in impulsive spending or risky behaviors after a significant life change might be quickly categorized as having bipolar disorder, when in reality, they are struggling to cope with a sudden transition.
While these behaviors may be distressing, they do not always indicate the presence of a psychiatric disease requiring medication. Instead, they may reflect normal reactions to adversity that should be addressed through support, coping strategies, and time.
The Risks of Overpathologizing Human Experience
The trend of pathologizing problems of living carries significant consequences. Studies have shown that psychiatric overdiagnosis leads to unnecessary medication use, stigma, and a shift in focus away from addressing social determinants of health. For instance, research suggests that antidepressants are prescribed to 1 in 4 U.S. adults, often for mild or situational distress rather than true clinical depression. Moreover, children—particularly boys—are diagnosed with ADHD at disproportionately high rates, sometimes as a response to difficulties in structured classroom settings rather than a true neurodevelopmental disorder.
Overpathologizing also impacts the credibility of psychiatry. If every struggle is framed as a disorder, the public may begin to view psychiatric diagnoses with skepticism, undermining trust in the profession and the legitimacy of serious mental illnesses.
A Case That Stuck With Me
I once treated a young man who had been brought to the hospital by his family after he quit his job, broke up with his girlfriend, and started making impulsive purchases. His parents were convinced he had bipolar disorder, having read online that sudden life changes and spending sprees were signs of mania. However, after spending time with him, it became clear that his actions were rooted in profound dissatisfaction with his life, not a mood disorder. He was struggling with feelings of stagnation, a lack of purpose, and a desire to redefine himself—not symptoms of an illness, but a human experience.
Despite my clinical assessment, his family was frustrated. They wanted a diagnosis, a label, a treatment plan—something concrete. It was difficult for them to accept that not every distressing experience fits neatly into a medical framework.
How Can Psychiatry Do Better?
Psychiatrists and mental health professionals must be intentional in distinguishing true mental illness from the expected emotional and behavioral responses to life’s challenges. Some ways to do this include:
A thorough biopsychosocial assessment that considers the role of environmental, cultural, and situational factors in a patient’s presentation.
The judicious use of psychiatric diagnoses, ensuring that labels are assigned only when they accurately reflect a disorder rather than a reaction to stress.
Education for patients and families about the natural spectrum of human emotions, helping them understand that distress does not always equate to disease.
Advocating for systemic solutions, such as better social support networks, financial resources, and access to therapy, so that emotional struggles are not automatically funneled into the medical system.
Addressing the Counterarguments
Some might argue that withholding a diagnosis could prevent patients from accessing the care they need. While it’s true that a psychiatric label can sometimes be a gateway to services and support, misdiagnosis can be just as harmful. Providing the wrong diagnosis can lead to unnecessary medication, reinforce a sense of pathology where none exists, and obscure the real sources of distress. The challenge for psychiatrists is to walk this fine line carefully—validating suffering without automatically medicalizing it.
Conclusion: A Call for Thoughtful Psychiatry
As psychiatrists, our role is not simply to diagnose and medicate, but to thoughtfully assess and guide. True psychiatric illness must be identified and treated appropriately, but we must also be cautious not to medicalize the normal, albeit painful, struggles of life. The goal should always be to help patients find real, meaningful solutions—whether that means therapy, life changes, or, in some cases, just the reassurance that what they are feeling is part of the human experience.
Many people spend their entire lives holding themselves back, often because they’re unconsciously addicted to the pain they cause themselves. When trauma hits, especially early in life, it has a way of sticking with us. In many ways, that pain shapes who we are, and the thought of letting it go feels like losing a part of ourselves. It can become a form of behavioral addiction.
But what if we could use that pain as fuel to push ourselves forward, to become the best version of who we are? It’s hard, especially when you’ve been picked on, or felt like you don’t fit in. We all just want to live authentically, to be true to ourselves.
I get it—I’ve been there too. If I can push through, so can you. It’s never easy, especially in tough times. But if there’s one thing I know, I’m not giving in.
The entactogen MDMA overlaps with the chemical structure of methamphetamine and mescaline and has biological effects similar to epinephrine, dopamine, and serotonin.
It increases the release of monoamines through the reversal of transporter proteins and reuptake inhibition specifically serotonin and norepinephrine. Not only does it block reuptake of serotonin and norepinephrine it enhances the release as well and inhibits VMAT preventing the packaging of monoamines into vesicles making more available for release. It also modulates glucocorticoids through the HPA axis, decreases amygdala and hippocampal activity, increases oxytocin, and increase prefrontal cortex activity.
Medical Use
MDMA started out as a therapeutic agent to enhance blood clotting for surgical procedures and trauma. Turns out it does not work very well for that indication, who would have thought. It’s currently listed as a schedule I substance (defined as having no accepted medical use, high abuse potential, and lack of accepted safety).
It was later discovered to have “empathogenic effects” helping individuals who use the medication to feel more connected to their fellow human beings. After all isn’t that what we are all after? A deep connection to others and people who truly understand us. The original name for the drug was empathy, but that has changed over the years to molly and escstcy. Personally, I like names that describe what a drug does, and empathy or empath is just so much more marketable don’t you think?
Why PTSD is a Big Problem
With several recent wars in both Iraq and Afghanistan, America has a PTSD problem with many combat veterans returning home and requiring treatment. If you ever treated patients with PTSD than you know it’s difficult and the therapy can be intense. Many patients are unable to sit with the discomfort required to reconsolidate these memories. Having worked at the VA for one year I was surprised by the number of vets with non-combat related PTSD. Honestly, they the vast majority of my cases were people who had accidents while working or in training and subsequently developed PTSD.
The idea is we need methods to enhance the efficacy and speed of trauma focused psychotherapies. What better way to do that than with empathy a medication that enhances feelings of connection. The basic idea being the patient would be given MDMA and then undergo psychotherapy and by using the medication it can influence fear extinction and memory reconsolidation. There are many mechanisms at play including effects on dopamine, serotonin, BDNF, cortisol, and oxytocin.
The concept of using a psychedelic drug to enhance the effects of psychotherapy is not a new concept, and was done for years using LSD and other compounds. What is different now, is we are trying to put the scientific rigor behind the studies to prove that it works better than placebo, and to learn more about the mechanism of action.
I want to point out that the main benefit of all these psychedelic medications seems to be enhanced neuroplasticity and the ability to form new connections in critical neurocircuits much easier than would otherwise be possible.
Benefits of MDMA Assisted Psychotherapy
-Increase blood flow to the vmPFC decreasing activation of the amygdala largely responsible for the fear response
-Enhance the production of BDNF which improves the long-term potentiation and memory consolidation
-Elevate the stress hormone cortisol which interacts with glucocorticoid receptors in the hippocampus to improve memory
-Elevates the prosocial neuropeptide oxytocin which decreases activation of the amygdala and enhances connection with the therapist
-Increased levels of dopamine which can destabilize the old memories and help with reconsolidation of new ones
-Increased serotonin levels resulting in prosocial and positive affective states.
The goal of PTSD treatment is to prevent the patient from being held hostage by these memories. We want to destabilize the old memories, modify them, and reconsolidate the new memories. The trauma still occurred, but the patient no longer has the same fear reaction to the traumatic memories.
MDMA-Assisted Therapy proved to be highly effective in individuals with severe PTSD.
-In this study investigators gave patients with PTSD 120-180 mg of MDMA along with a trauma focused psychotherapy. There were significant rates of both response and remission compared to placebo.
-MDMA was well tolerated
-It was granted breakthrough status by the FDA
-This was a big deal in the news and media outlets
-It needs to be replicated to confirm the results
Potential Adverse Effects of MDMA
-Potential for abuse and diversion (probably no take homes)
-Possible hyperthermia or hyponatremia (more common in the recreational use environment than clinical)
-People often engage in prolonged physical activity in hot environments and do not consume enough water this results in dehydration and possible hyperthermia (think large dance party)
-In the opposite case the person overcompensates and overconsumes water diluting their blood and causing hyponatremia. Excess of anything can cause problems and water is no exception.
Blue Monday and Black Tuesday
-Use of MDMA can cause low mood, irritability, and fatigue. It can occur for days after recreational use.
-In the clinical setting, fatigue, anxiety, low mood, headaches, and nausea can occur in the week after treatment
